PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatr Infect Dis J. Author manuscript; available in PMC Dec 4, 2012.
Published in final edited form as:
PMCID: PMC3514443
NIHMSID: NIHMS380276
Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Children in Peru
Marie E. Wang, MD,* Maria E. Castillo, MD, Silvia M. Montano, MD, MPH, and Joseph R. Zunt, MD, MPH§
*Department of Pediatrics, School of Medicine, Stanford University School of Medicine, Stanford, CA
Department of Pediatrics, School of Medicine, Universidad Peruana Cayetano Heredia and Instituto Nacional del Salud del Niño, Lima, Peru
Department of Virology, US Naval Medical Research Center Detachment, Lima, Peru
§Departments of Neurology, Global Health, and Medicine (Infectious Diseases), School of Medicine, University of Washington, Seattle, WA
Address for correspondence: Marie Wang, MD, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305. marie.wang/at/stanford.edu
Background
Immune reconstitution inflammatory syndrome (IRIS) after initiating highly active antiretroviral therapy (HAART) has not been widely studied in children, especially in resource-poor settings.
Methods
Retrospective cohort study of HIV-infected children initiating HAART between 2001 and 2006 at a tertiary pediatric hospital in Lima, Peru. Charts were reviewed for 1 year after HAART initiation. IRIS was defined as a HAART-associated adverse event caused by an infectious or inflammatory condition in patients with documented virologic or immunologic success.
Results
Ninety-one children (52% female) received HAART for at least 1 year. Median age at initiation was 5.7 years; 91% were ART naive and 73% had CDC stage C disease. The incidence of IRIS was 19.8 events per 100 person years (95% CI: 11.5–28.0). Median time to IRIS was 6.6 weeks after HAART initiation (range: 2–32 weeks). There were 18 IRIS events, 11 unmasking and 7 paradoxical. These included associations with Mycobacterium tuberculosis in 4 cases, Bacillus Calmette Guerin lymphadenitis in 1 case, varicella zoster virus in 6 cases and herpes simplex labialis in 6 cases. Children who developed IRIS had a higher baseline HIV viral load (P = 0.02) and an indicator of malnutrition (P = 0.007) before HAART initiation.
Conclusion
IRIS occurred in 20% of HIV-infected children starting HAART in Peru and was associated with more advanced disease and malnutrition. Future research is needed to examine specific risk factors associated with pediatric IRIS to allow prompt identification and treatment of IRIS.
Keywords: immune reconstitution inflammatory syndrome, HIV, AIDS, HAART, children
Since the introduction of highly active antiretroviral therapy (HAART), morbidity and mortality due to HIV infection have decreased considerably.1 Some patients develop an inflammatory response shortly after starting HAART, despite an increase in CD4 lymphocyte count and decreasing viral load.2-4 This clinical phenomenon has been called immune reconstitution syndrome, immune reconstitution disease, and immune reconstitution inflammatory syndrome (IRIS). IRIS can produce 2 distinct clinical syndromes: unmasking and paradoxical.5-8 Unmasking IRIS is an occult infection unmasked by immune system recovery after HAART initiation in patients who had no previous signs or symptoms of the infection. Paradoxical IRIS is the symptomatic recurrence of a successfully treated infection driven by antigen-specific immune activation in the setting of few or no viable organisms; cultures are usually negative due to previous effective treatment.
IRIS has been most often described in adults. Retrospective studies report 17% to 32% of adults initiating HAART develop IRIS.3,6,9,10 The wide variation in prevalence can be partially explained by different IRIS definitions used, pathogens included, degree of immunosuppression and prevalence of opportunistic infections (OIs) in the cohorts studied. The first prospective study of IRIS in South African adults with AIDS reported a 10% incidence of IRIS during the first 6 months of HAART, with most IRIS events associated with a low morbidity.11 A variety of pathogens have been associated with IRIS, including varicella zoster virus, Mycobacterium spp., Cryptococcus neoformans, Molluscum contagiosum, cytomegalovirus, and others.4
Few studies have examined incidence and etiologies of IRIS in children, and we are not aware of any reports of pediatric IRIS in Latin America. One retrospective study from the United States described varicella zoster associated with IRIS in 11% of children starting HAART.12 The only prospective study of incident pediatric IRIS reported an incidence of 19% among Thai children, with the majority associated with Mycobacterial spp.13 Other case reports have identified Mycobacterium avium complex, C. neoformans,13 and sarcoidosis associated with IRIS.14,15 The objectives of this study were to retrospectively examine the incidence, pathogens and clinical spectrum of IRIS in a cohort of children starting HAART in Peru.
Patient Population
A retrospective study of HIV-infected children at the Instituto Nacional de Salud del Niño, the main tertiary pediatric referral center in Lima, Peru. Inclusion criteria included starting HAART between July 2001 and December 2006, continuing HAART for at least 1 year, and baseline measures of CD4 counts and HIV viral load before initiating HAART. This study was approved by the Research Ethics Committee at Instituto Nacional de Salud del Niño.
Clinical Histories
Medical charts were abstracted for data regarding demographics, clinical, and virologic data and diagnostic test results. HIV infection was diagnosed by enzyme-linked immunoassay (ELISA, Diagnostic Bio-Probes, Milan, Italy) with confirmation by indirect fluorescent antibody (Instituto Nacional del Salud del Niño, Lima). HIV stage was determined using the Centers for Disease Control Classification for HIV in children.16 Prior to starting HAART, patients received a physical examination, tuberculin skin test, chest x-ray, CD4 count, HIV viral load, and were screened for opportunistic infections. Treatment was initiated for any infection detected during screening.
After starting HAART, children underwent monthly clinical visits. Medical charts were reviewed for 1 year after HAART initiation. CD4 profiles were measured every 3 months, and viral load every 6 months. CD4 percentages were calculated using absolute CD4 count divided by absolute lymphocyte count closest to the time CD4 count was measured. CD4 count was assessed using flow cytometry (BD FACSCount, BD Biosciences). Viral load was assessed using the Roche Amplicor assay (Roche Diagnostic, Indianapolis, IN) with a lower detection limit of 400 copies/mL.
IRIS Definition
We first identified HAART-associated adverse events that had previously been associated with IRIS in children with immunologic or virologic success.4 Immunologic success was defined as an increase in baseline CD4 count greater than 5% or a total CD4 cell count greater than 250 cells/mL closest to the time of the IRIS event.12,13 Virologic success was defined as a decrease in plasma HIV RNA titer >1 log10 or achieving a titer of <400 copies/mL closest to the time of the IRIS event.12,13 Suspected IRIS cases were verified against the pediatric IRIS case definition and suspected TB-IRIS cases were verified against the pediatric TB-IRIS definition established by the International Network of the Study of HIV-associated IRIS.5,17 We subsequently defined adverse infectious or inflammatory events as either: (1) paradoxical IRIS if the child had a prior documented history of the OI or as (2) unmasking IRIS if the event was a new onset OI associated with HAART.
Diagnoses of varicella zoster virus and mucocutaneous herpes (HSV) infection were based on clinical signs and symptoms. Tuberculosis was diagnosed by a combination of clinical, radiologic, and microbiologic confirmation using culture or polymerase chain reaction DNA amplification methods. Bacillus Calmette-Guerin (BCG) adenitis was diagnosed from clinical signs and symptoms because the hospital did not have laboratory capability to identify Mycobacterium bovis.
Malnutrition was measured using WHO Growth Reference Data.18 Weight-for-age and height-for-age z scores were calculated for each child, and weight-for-height z scores were calculated for children ages ≤5 years using WHO Anthro (version 2.02, Geneva, Switzerland). Children with z scores less than 2 standard deviations below the mean in any of the 3 categories were classified as having malnutrition. No information on specific nutritional supplementation for malnutrition was collected during this study. Supplemental feeding and micronutrient supplementation for hospitalized children were determined by the patient’s physician on a case-by-case basis. Children in the outpatient setting who were 2 years of age or older and receiving HAART, regardless of nutritional state, were given a bag of groceries each month and mothers of infants 6 months of age or younger received formula.
Statistical Analysis
The primary statistical comparison was IRIS cases versus cohort controls. For continuous variables, such as HIV viral load and CD4, independent t tests were used. Categorical variables were analyzed using Pearson χ2 test. Two-sided tests were used with P < 0.05 considered statistically significant (SPSS 15.0, Chicago, IL).
Patient Population
Between July 2001 and December 2006, 104 children were started on HAART; 91 (87.5%) met inclusion criteria. Thirteen patients were excluded because of missing baseline CD4 counts or viral load (n = 6), insufficient time receiving HAART (n = 5), or unavailable medical records (n = 2). HAART regimens included zidovudine, lamivudine, and nelfinavir (n = 64); zidovudine, lamivudine, stavudine (n = 26); and stavudine, didanosine, and nelfinavir (n = 1). Children were predominantly in CDC Category C at HAART initiation (73%) and 91% were ART naive. Fifty-three percent were male and average age at HAART initiation was 6 years (range, 4 months–16 years). Acquisition of HIV was mainly through vertical transmission (90%), but also from transfusion (5%), sexual transmission (1%), and unknown (3%). Baseline demographic data and laboratory data are detailed in Table 1.
TABLE 1
TABLE 1
Baseline Demographic and Laboratory Data of Children Who Initiated HAART
IRIS Characteristics
Of the 91 children, 18 (20%, 95% confidence interval: 11.5–28.0) developed an HAART-associated adverse event consistent with IRIS. The median time of IRIS onset was 6.6 weeks (range, 2–34 weeks) after initiating HAART. Of the 18 IRIS events, 12 were unmasking IRIS and 6 paradoxical IRIS. There were 6 cases of varicella zoster, 6 cases of HSV labialis, 5 cases of M. tuberculosis and 1 case of BCG adenitis. No IRIS event necessitated HAART interruption. IRIS resolved in all 18 patients. No children died shortly after HAART initiation and there was no IRIS related mortality within 1 year of initiating HAART. Details of patients who developed IRIS are shown in the Table (Supplemental Digital Content 1, http://links.lww.com/INF/A174).
Of the 5 IRIS cases associated with M. tuberculosis (TB) infection, there were 2 cases of pulmonary TB, 2 with combined pulmonary and extrapulmonary TB, and 1 with ganglionic TB. Four were confirmed by culture or PCR. The case without culture confirmation was a pulmonary and peritoneal infection diagnosed by chest radiography and abdominal ultrasonography. Of the 5 TB-IRIS events, 1 was paradoxical having been diagnosed with M. tuberculosis 3 years previously, while the other 3 were newly diagnosed (unmasking TB-IRIS). Four patients required hospitalization. All patients were treated with anti-TB therapy and had resolution of infection. There was 1 case of BCG adenitis diagnosed clinically in a child who presented with a subcutaneous abscess that resolved without antimicrobial treatment.
There were 6 cases of varicella zoster infection; all with a characteristic dermatomal presentation. Four had a prior episode of varicella zoster infection before starting HAART. All were treated with acyclovir and responded to treatment. Three children required hospitalization. There were 6 cases of herpes simplex labialis. One patient had HSV labialis before starting HAART. Three patients were treated with acyclovir, 3 received no treatment, and symptoms resolved in all patients.
When considering paradoxical versus unmasking IRIS, the 6 cases of paradoxical IRIS were caused by varicella zoster virus (4 cases), Mycobacterium spp. (1 case), and herpes simplex labialis (1 case). Unmasking IRIS was caused by Mycobacterium spp. (5 cases), herpes simplex labialis (5 cases), and varicella zoster virus (2 cases).
The pre-HAART mean viral load was significantly greater in IRIS cases than in non-IRIS patients (P = 0.02). There was no significant difference in CD4 or CD8 count, age, gender, mode of HIV acquisition (P = 0.9), or HAART regimen (P = 0.53). Although more children with CDC Category C disease had IRIS than children with Category A or B disease, the difference was not significant (24% vs. 8%, OR = 3.68, P = 0.14).
Children with IRIS were more likely to have 1 indicator of malnutrition compared with children without IRIS (Table 2, P = 0.007). When children ages 0 to 5 and 6 to 17 were analyzed separately, the difference also persisted in the age 6 to 17 group (P = 0.049). Logistic regression analysis adjusting for age and sex revealed that malnutrition and baseline viral load were significantly associated with IRIS (beta coefficient and P values: 4.73 and 0.015, 1.00 and 0.014, respectively). Baseline CD4 count did not confound this association and was not retained in the final model.
TABLE 2
TABLE 2
Percentage of Children With an Indicator of Malnutrition
IRIS most commonly presents with an infectious etiology, and has been well described after starting HAART.4 This is the first study to examine pediatric IRIS in Latin America. The 20% incidence found in this study is similar to the 19% prospective IRIS incidence reported among children in Thailand. The range of infectious causes encountered in this study is similar to those reported previously.12,13,19
The majority of IRIS cases (67%) were associated with unmasking of infection and only 33% were associated with recurrence of previously treated infection (paradoxical IRIS). Studies of adults in the developing world have noted 50% to 80% of cases resulted from paradoxical IRIS.3,11 Increased screening at HAART initiation can decrease the number of unmasking infections, as demonstrated by 1 Ugandan study that showed a 50% decrease in unmasking TB infections in children after initiating tuberculin skin test screening before starting the therapy.20
The rate of TB-IRIS cases we found was within the wide range reported in the literature for children and adults. Prospective studies have found 10% of IRIS cases associated with TB in children and 41% of IRIS cases associated with TB in adults.11,13 Herpes viruses have also been commonly implicated in IRIS in children and adults, with varicella zoster virus being one of the most commonly reported causes of IRIS in children.12,13 The first report of IRIS in children found an incidence of 22.9 cases of varicella zoster virus per 100 person-years in the first 6 months after HAART,12 and the Thai study found 22% of IRIS cases in children caused by varicella zoster virus.13 Regarding HSV infections, while they can potentially cause more serious disease such as HSV encephalitis, the cases observed in our study were mild and resolved with treatment. Less severe infection may have been due to easy recognition of HSV labialis and early initiation of treatment. The Thai study showed that 19% of pediatric IRIS cases were related to HSV, including 1 case of HSV encephalitis,13 and the only prospective study in adults reported 9.1% of IRIS cases associated with HSV infection.11
Our study detected an association between IRIS and malnutrition. In children, malnutrition can cause further immunosuppression,21 and refeeding alone can produce paradoxical IRIS-like reactions.22 Although we did not collect information regarding nutritional supplementation for each child in this study, all children received monthly groceries and were perhaps at lower risk for this complication. HIV infection can also cause malnutrition through gastrointestinal illness, cachexia, and anemia.21 Thus, it is plausible that HIV-infected children with underlying malnutrition may develop an exaggerated immune response upon starting HAART. As our study only examined height and weight as indicators of malnutrition, future studies should include more detailed examination of nutrition measures to further examine the relationship between malnutrition and IRIS, as well as the association of refeeding, focusing on children with moderate to extreme malnutrition.
The immunologic mechanism of IRIS is not well defined, but experts suggest it is an antigen-driven process occurring when the immune system becomes dysregulated during the early period of effective antiretroviral therapy. French23 proposed that immune reconstitution is due to an imbalanced cellular immune response against pathogen-specific antigens, and depending on the pathogen, produces a TH1, Th17, or CD8+ response. Bonham et al24 postulated that IRIS occurs during antigen clearance when antigen-specific immunity and homeostatic T-regulatory function is recovering, and that specific cytokines may serve as biomarkers for different forms of IRIS. Given the high prevalence of tuberculosis in Peru, we are not surprised that tuberculosis was a common manifestation of IRIS. Additional research is needed to further elucidate the immunopathogenesis of IRIS in the developed and developing world—where endemic infections are often different.
The most significant limitation of our study is the lack of an objective definition of IRIS with objective biomarkers for diagnosis. Furthermore, because of the retrospective nature of this study, CD4 lymphocyte counts and HIV viral loads were not consistently available before and after HAART initiation and at the time of the IRIS event. The hospital did not measure CD4 and CD8 lymphocyte percentages so they were calculated from total lymphocyte counts from the nearest date, which provided an approximation of the true CD4 and CD8 lymphocyte percentage. Finally, the number of patients in the study was too small to make firm conclusions about specific risk factors, however, the incidence and clinical spectrum were similar to other publications.
In conclusion, IRIS was a common occurrence in Peruvian HIV-infected children during the first year after initiation of HAART therapy. Clinicians should be aware of both the unmasking of subclinical infections as well as the paradoxical recrudescence of successfully treated infections in children shortly after initiating HAART. Future research should examine specific risk factors associated with IRIS in children so that children who are at highest risk of IRIS can be identified and treated promptly.
Supplementary Material
Supplemental Table
Acknowledgments
The authors thank Dr. David Boulware for his helpful comments during the preparation of the manuscript.
Supported by the NIH/Fogarty International Clinical Research Scholars Program through NIH Research Grant D43 TW000007.
Footnotes
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.pidj.com).
1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. [PubMed]
2. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2000;1:107–115. [PubMed]
3. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418–427. [PubMed]
4. Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4:9. [PMC free article] [PubMed]
5. Boulware D, Callens S, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS. 2008;3:461–467. [PMC free article] [PubMed]
6. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615–1627. [PubMed]
7. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167–170. [PubMed]
8. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–523. [PMC free article] [PubMed]
9. Jevtovic DJ, Salemovic D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005;6:140–143. [PubMed]
10. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399–406. [PubMed]
11. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008;22:601–610. [PubMed]
12. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol. 2004;113:742–746. [PubMed]
13. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2006;25:53–58. [PMC free article] [PubMed]
14. Steenhoff AP, Wood SM, Shah SS, et al. Cutaneous Mycobacterium avium complex infection as a manifestation of the immune reconstitution syndrome in a human immunodeficiency virus-infected child. Pediatr Infect Dis J. 2007;26:755–757. [PubMed]
15. Viani RM. Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. Pediatr Infect Dis J. 2002;21:435–438. [PubMed]
16. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43
17. International Network of the Study of HIV-associated IRIS. Case definition: consensus criteria for diagnosis of pediatric TB IRIS 2008. [October 11, 2008]; Available at: http://www.inshi.umn.edu/inshi/definitions/Peds_TB_IRIS.html.
18. de Onis M, Onyango A, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85:661–668. [PubMed]
19. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007;11:417–423. [PubMed]
20. Bakeera-Kitaka S, Dhabangi A, Namulema E. Immune reconstitution inflammatory syndrome and post-antiretroviral tuberculosis among HIV-infected Ugandan children. Infectious Diseases Society of America Annual Conference; 4–7 October, 2007; San Diego, CA. abstract.
21. Beisel WR. Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. J Nutr. 1996;126:2611S–2615S. [PubMed]
22. Murray MJ, Murray AB, Murray NJ, et al. Infections during severe primary undernutrition and subsequent refeeding: paradoxical findings. Aust NZ J Med. 1995;25:507–511. [PubMed]
23. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48:101–107. [PubMed]
24. Bonham S, Meya DB, Bohjanen PR, et al. Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med. 2008;2:349–361. [PMC free article] [PubMed]